This roundtable series examines therapeutic options for patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer, as discussed by key opinion leaders and participants at virtual live events.
Repotrectinib Shows Improvement Over First-Generation TKIs in ROS1+ NSCLC
January 2nd 2024Firas B. Badin, MD, discusses the improvements seen with repotrectinib compared with first-generation ROS1-targeting tyrosine kinase inhibitors for patients with advanced ROS1-positive non–small cell lung cancer.
Velcheti Addresses Promising Data with Repotrectinib in ROS1+ NSCLC
February 20th 2024In the first article of a 2-part series, Vamsidhar Velcheti, MD, MBA, discussed why patients with lung cancer may experience dizziness with repotrectinib and why the efficacy data behind this therapy are considered impressive.
Discussing Non-Clinical Barriers to NGS Testing for NSCLC
May 15th 2024During a Case-Based Roundtable® event, Julia Rotow, MD, led a discussion on the non-clinical barriers that impact the use of using next-generation sequencing for patients with certain mutations of their non–small cell lung cancer in the first article of a 2-part series.